Plain-English translation of NCT06305182 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a medication called , a hormone that may help people with anorexia nervosa. The study focuses on whether this treatment can improve depression and help patients gain weight. Half of the 50 participants will receive the real medication, and half will receive a placebo (inactive treatment) to see which works better.
Anorexia nervosa is a serious eating disorder that affects many young people and is difficult to treat. Research shows that people with anorexia have very low levels of a hormone called leptin, which may contribute to both the physical symptoms and the depression that often comes with the disorder. This medication aims to restore that hormone and help ease both mood and eating-related problems.
You likely qualify if…
You likely don't qualify if…
You will be hospitalized and receive a daily injection under the skin for 14 days. Half of participants will receive the study medication and half will receive placebo; neither you nor the researchers will know which at first. During this time, the team will monitor your mood, weight, blood work, and brain activity through scans to see if the treatment helps with depression and eating disorder symptoms.
AI-generated summary from trial data · Jun 14, 2026 · Not medical advice
Switzerland